Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$268.74 +0.7%	$292.52	$262.21 ▼ $495.55	$35.65B	0.27	1.50 million shs	1.14 million shs
BIIB Biogen	$200.62 +1.5%	$199.60	$124.56 ▼ $219.72	$29.19B	0.16	1.46 million shs	1.03 million shs
INCY Incyte	$116.69 +0.8%	$106.38	$69.69 ▼ $119.60	$23.13B	0.76	1.66 million shs	956,158 shs
NBIX Neurocrine Biosciences	$174.15 +0.8%	$165.18	$122.14 ▼ $181.18	$17.36B	0.39	1.07 million shs	1.10 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+0.66%	-5.09%	-6.75%	-12.04%	-17.47%
BIIB Biogen	+1.46%	-3.97%	+1.74%	+8.81%	+53.17%
INCY Incyte	+0.78%	+0.03%	+11.77%	+23.29%	+65.07%
NBIX Neurocrine Biosciences	+0.85%	+1.52%	+7.87%	+36.42%	+30.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$268.74 +0.7%	$292.52	$262.21 ▼ $495.55	$35.65B	0.27	1.50 million shs	1.14 million shs
BIIB Biogen	$200.62 +1.5%	$199.60	$124.56 ▼ $219.72	$29.19B	0.16	1.46 million shs	1.03 million shs
INCY Incyte	$116.69 +0.8%	$106.38	$69.69 ▼ $119.60	$23.13B	0.76	1.66 million shs	956,158 shs
NBIX Neurocrine Biosciences	$174.15 +0.8%	$165.18	$122.14 ▼ $181.18	$17.36B	0.39	1.07 million shs	1.10 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+0.66%	-5.09%	-6.75%	-12.04%	-17.47%
BIIB Biogen	+1.46%	-3.97%	+1.74%	+8.81%	+53.17%
INCY Incyte	+0.78%	+0.03%	+11.77%	+23.29%	+65.07%
NBIX Neurocrine Biosciences	+0.85%	+1.52%	+7.87%	+36.42%	+30.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.85	Moderate Buy	$452.13	68.24% Upside
BIIB Biogen	2.53	Moderate Buy	$220.57	9.94% Upside
INCY Incyte	2.36	Hold	$111.10	-4.79% Downside
NBIX Neurocrine Biosciences	2.96	Moderate Buy	$194.05	11.43% Upside

Current Analyst Ratings Breakdown

Latest NBIX, ALNY, BIIB, and INCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/23/2026	INCY Incyte	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$103.00 ➝ $104.00
7/23/2026	INCY Incyte	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$105.00 ➝ $110.00
7/22/2026	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$420.00 ➝ $400.00
7/21/2026	BIIB Biogen	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$260.00 ➝ $280.00
7/21/2026	BIIB Biogen	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$217.00 ➝ $215.00
7/21/2026	INCY Incyte	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$140.00
7/21/2026	NBIX Neurocrine Biosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$175.00 ➝ $200.00
7/17/2026	NBIX Neurocrine Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$175.00 ➝ $200.00
7/15/2026	INCY Incyte	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
7/14/2026	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
7/14/2026	INCY Incyte	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 7/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	9.66	$2.81 per share	95.49	$5.97 per share	45.02
BIIB Biogen	$9.89B	2.99	$22.95 per share	8.74	$124.45 per share	1.61
INCY Incyte	$5.14B	4.53	$6.23 per share	18.74	$26.32 per share	4.43
NBIX Neurocrine Biosciences	$2.86B	6.12	$5.06 per share	34.45	$32.63 per share	5.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$3.66	73.43	26.04	N/A	11.72%	85.76%	10.32%	7/30/2026 (Estimated)
BIIB Biogen	$1.29B	$9.32	21.53	12.10	N/A	13.81%	12.83%	8.01%	7/29/2026 (Estimated)
INCY Incyte	$1.29B	$7.08	16.48	14.94	1.05	26.71%	26.66%	19.77%	7/28/2026 (Estimated)
NBIX Neurocrine Biosciences	$478.60M	$6.49	26.83	17.50	0.69	21.55%	19.79%	13.82%	7/30/2026 (Estimated)

Latest NBIX, ALNY, BIIB, and INCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2026	Q2 2026	ALNY Alnylam Pharmaceuticals	$1.63	N/A	N/A	N/A	$1.32 billion	N/A
7/30/2026	Q2 2026	NBIX Neurocrine Biosciences	$1.64	N/A	N/A	N/A	$890.05 million	N/A
7/29/2026	Q2 2026	BIIB Biogen	$3.15	N/A	N/A	N/A	$2.46 billion	N/A
7/28/2026	Q2 2026	INCY Incyte	$2.10	N/A	N/A	N/A	$1.47 billion	N/A
4/30/2026	Q1 2026	ALNY Alnylam Pharmaceuticals	$0.8720	$1.99	+$1.1180	$1.51	$1.12 billion	$1.17 billion
4/29/2026	Q1 2026	BIIB Biogen	$2.95	$3.57	+$0.62	$2.15	$2.29 billion	$2.48 billion
4/28/2026	Q1 2026	INCY Incyte	$1.38	$1.81	+$0.43	$1.47	$1.22 billion	$1.27 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.94	3.13	3.06
BIIB Biogen	0.34	3.06	2.41
INCY Incyte	0.01	3.68	3.60
NBIX Neurocrine Biosciences	N/A	2.93	2.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
INCY Incyte	96.97%
NBIX Neurocrine Biosciences	92.59%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
BIIB Biogen	0.25%
INCY Incyte	16.20%
NBIX Neurocrine Biosciences	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.51 million	132.37 million	Optionable
BIIB Biogen	7,500	147.64 million	147.27 million	Optionable
INCY Incyte	2,844	199.78 million	167.42 million	Optionable
NBIX Neurocrine Biosciences	2,000	100.55 million	95.93 million	Optionable

NBIX, ALNY, BIIB, and INCY Headlines

Recent News About These Companies

Neurocrine Biosciences, Inc. $NBIX Shares Purchased by First Trust Advisors LP

4 hours ago | marketbeat.com

Neurocrine Biosciences (NBIX) Stock Trades Fair On Earnings But Mixed On Value

July 23 at 5:11 PM | finance.yahoo.com

Neurocrine Biosciences Announces Key Leadership Hiring, Promotions

July 23 at 4:05 PM | prnewswire.com

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

July 23 at 11:01 AM | zacks.com

Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Swiss National Bank

July 23 at 4:55 AM | marketbeat.com

9,511 Shares in Neurocrine Biosciences, Inc. $NBIX Acquired by Aureus Asset Management LLC

July 23 at 3:27 AM | marketbeat.com

Neurocrine Biosciences (NBIX) Projected to Release Earnings on Thursday

July 23 at 2:10 AM | americanbankingnews.com

Neurocrine Biosciences (NBIX) Projected to Post Earnings on Thursday

July 23 at 2:10 AM | marketbeat.com

Guggenheim Raises Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $200.00

July 23 at 1:24 AM | americanbankingnews.com

Neurocrine Biosciences (NBIX) Appoints Samir Siddhanti As Chief Business Officer

July 22 at 5:54 PM | finance.yahoo.com

Neurocrine Biosciences, Inc.: Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer

July 22 at 7:52 AM | finanznachrichten.de

Mediolanum International Funds Ltd Has $1.30 Million Position in Neurocrine Biosciences, Inc. $NBIX

July 22 at 5:03 AM | marketbeat.com

Hsbc Holdings PLC Has $24.30 Million Holdings in Neurocrine Biosciences, Inc. $NBIX

July 22 at 4:31 AM | marketbeat.com

California Public Employees Retirement System Purchases 25,620 Shares of Neurocrine Biosciences, Inc. $NBIX

July 22 at 3:37 AM | marketbeat.com

Bank of New York Mellon Corp Reduces Position in Neurocrine Biosciences, Inc. $NBIX

July 22 at 3:28 AM | marketbeat.com

Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer

July 21 at 4:05 PM | prnewswire.com

Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, Guggenheim Analyst Says

July 21 at 10:17 AM | marketbeat.com

Summit Global Investments Has $2.25 Million Stake in Neurocrine Biosciences, Inc. $NBIX

July 21 at 6:15 AM | marketbeat.com

79,577 Shares in Neurocrine Biosciences, Inc. $NBIX Acquired by SEB Asset Management AB

July 21 at 5:28 AM | marketbeat.com

Andra AP fonden Buys 80,291 Shares of Neurocrine Biosciences, Inc. $NBIX

July 21 at 3:19 AM | marketbeat.com

Principal Financial Group Inc. Has $31.38 Million Holdings in Neurocrine Biosciences, Inc. $NBIX

July 20, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NBIX, ALNY, BIIB, and INCY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$268.74 +1.75 (+0.66%)

Closing price 07/23/2026 04:00 PM Eastern

Extended Trading

$273.21 +4.47 (+1.66%)

As of 07:53 AM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$200.62 +2.88 (+1.46%)

Closing price 07/23/2026 04:00 PM Eastern

Extended Trading

$200.29 -0.33 (-0.16%)

As of 07:45 AM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Incyte NASDAQ:INCY

$116.69 +0.90 (+0.78%)

Closing price 07/23/2026 04:00 PM Eastern

Extended Trading

$116.50 -0.19 (-0.16%)

As of 05:09 AM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Neurocrine Biosciences NASDAQ:NBIX

$174.15 +1.46 (+0.85%)

Closing price 07/23/2026 04:00 PM Eastern

Extended Trading

$175.76 +1.60 (+0.92%)

As of 07:20 AM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NBIX, ALNY, BIIB, and INCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NBIX, ALNY, BIIB, and INCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NBIX, ALNY, BIIB, and INCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NBIX, ALNY, BIIB, and INCY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Incyte NASDAQ:INCY

Neurocrine Biosciences NASDAQ:NBIX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NBIX, ALNY, BIIB, and INCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NBIX, ALNY, BIIB, and INCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NBIX, ALNY, BIIB, and INCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NBIX, ALNY, BIIB, and INCY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Incyte NASDAQ:INCY

Neurocrine Biosciences NASDAQ:NBIX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools